Macular Degeneration Treatment Market Opportunities Forecast 2022-28

According to Precision Business Insights (PBI), the latest report, the macular degeneration treatment market is expected to be valued at USD 8,457.3 million in 2022, growing at a 7.3% CAGR from 2022 to 2028. The primary driver of the expansion of the global Macular Degeneration Treatment market growing burden of retinal disorders, increase in the geriatric population, and increasing investment for research and development in the medical sector.

View the detailed report description here - https://precisionbusinessinsights.com/market-reports/macular-degeneration-treatment-market/

Wet Macular Degeneration Segment to Dominate the Macular Degeneration Treatment Market:
Based on the type, the wet macular degeneration segment is expected to account for a larger revenue share in the global Macular Degeneration Treatment market, with a value share worldwide. Wet macular degeneration is a beginning of a distinctive growth of blood vessels beneath the retina. These overgrown blood vessels drip blood, which obstructs the clarity of central vision leading to macular degeneration. According to Foundation 2020, during the COVID-19 pandemic, the hospitals provided services to patients with wet AMD to have intraocular anti-VEGF injections to protect vision. This was given at the regularity recommended by an ophthalmologist, which can vary from patient to patient depending on how dynamically the abnormal blood vessels in the retina are leaking. Moreover, further advanced development in wet macular degeneration will expect to increase the demand, consequently expanding the market for macular degeneration treatment

North America Macular Degeneration Treatment Market:
North America leads the Macular degeneration treatment market over the forecasted period owing to the presence of prominent key players, rise in the occurrences of eye disorders, growing geriatric population, favorable reimbursement policies, and technologically advanced healthcare infrastructure in this region. Asia-Pacific is witnessing a significant share in the upcoming few years of growth due to the escalation in the prevalence of macular degeneration, huge investment in the healthcare sector, rising awareness about health, and a rise in disposable income among a large section of the people.

Strategic New Product Launches, Mergers, Acquisitions, and Agreements are the key strategies adopted by market players:
The global Macular Degeneration Treatment market further reveals that the key players are increasingly adopting strategies such as the launch of newer products, product launches, and long-term alliances to improve market revenue share and gain significant geographic presence across the region. For instance, In September 2020, the United Food and Drug Administration (FDA) approved the fast-track designation of GT005, an investigational, one-time, AAV-based gene therapy for the treatment of geographic atrophy (GA).

Request sample report at: https://precisionbusinessinsights.com/request-sample/?product_id=59059

The macular degeneration treatment market is segmented based on type, stage of disease, route of administration, distribution channel, and geography.
Based on the type, the market is segmented into the following:
• Wet AMD
• Dry AMD

Based on the stage of disease, the market is segmented into the following:
• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Based on the route of administration, the market is segmented into the following:
• Intravenous Route
• Intravitreal Route

Based on the distribution channel, the market is segmented into the following:
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

Based on geography, the market is segmented into the following:
• North America
• Europe
• The Asia Pacific
• Latin America
• MEA

Request Methodology: https://precisionbusinessinsights.com/request-methodology?product_id=59059

Key players' profiles in the macular degeneration treatment market report are Hoffmann-La Roche Ltd, Novartis AG, Pfizer, Kanghong Pharma, Bausch Health Companies Inc., Bayer AG, REGENXBIO Inc., Aerie Pharmaceutical Inc, Regeneron Pharmaceuticals Inc., and Opthea.

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 85278174

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.